These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31434215)

  • 1. Lipolytic Effects of 3-Iodothyronamine (T1AM) and a Novel Thyronamine-Like Analog SG-2 through the AMPK Pathway.
    Rogowski M; Bellusci L; Sabatini M; Rapposelli S; Rahman SM; Chiellini G; Assadi-Porter FM
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31434215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metabolic suppressor 3-iodothyronamine enhances lipolysis in 3T3-L1 adipocytes via activation of the adenosine monophosphate-activated protein kinase/forkhead box O1 signaling pathway.
    Kim M; Park K; Choi I
    J Physiol Pharmacol; 2020 Jun; 71(3):. PubMed ID: 33077693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous 3-Iodothyronamine (T1AM) and Synthetic Thyronamine-like Analog SG-2 Act as Novel Pleiotropic Neuroprotective Agents Through the Modulation of SIRT6.
    Bellusci L; Runfola M; Carnicelli V; Sestito S; Fulceri F; Santucci F; Lenzi P; Fornai F; Rapposelli S; Origlia N; Zucchi R; Chiellini G
    Molecules; 2020 Feb; 25(5):. PubMed ID: 32110992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake of 3-iodothyronamine hormone analogs inhibits the growth and viability of cancer cells.
    Rogowski M; Gollahon L; Chellini G; Assadi-Porter FM
    FEBS Open Bio; 2017 Apr; 7(4):587-601. PubMed ID: 28396842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of gene expression by 3-iodothyronamine: genetic evidence for a lipolytic pattern.
    Mariotti V; Melissari E; Iofrida C; Righi M; Di Russo M; Donzelli R; Saba A; Frascarelli S; Chiellini G; Zucchi R; Pellegrini S
    PLoS One; 2014; 9(11):e106923. PubMed ID: 25379707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-Iodothyronamine and 3,5,3'-triiodo-L-thyronine reduce SIRT1 protein expression in the HepG2 cell line.
    Sacripanti G; Lorenzini L; Bandini L; Frascarelli S; Zucchi R; Ghelardoni S
    Horm Mol Biol Clin Investig; 2020 Mar; 41(1):. PubMed ID: 32114521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-Iodothyronamine Decreases Expression of Genes Involved in Iodide Metabolism in Mouse Thyroids and Inhibits Iodide Uptake in PCCL3 Thyrocytes.
    Schanze N; Jacobi SF; Rijntjes E; Mergler S; Del Olmo M; Hoefig CS; Khajavi N; Lehmphul I; Biebermann H; Mittag J; Köhrle J
    Thyroid; 2017 Jan; 27(1):11-22. PubMed ID: 27788620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3-Iodothyronamine reduces insulin secretion in vitro via a mitochondrial mechanism.
    Lehmphul I; Hoefig CS; Köhrle J
    Mol Cell Endocrinol; 2018 Jan; 460():219-228. PubMed ID: 28754352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Insights into the Potential Roles of 3-Iodothyronamine (T1AM) and Newly Developed Thyronamine-Like TAAR1 Agonists in Neuroprotection.
    Bellusci L; Laurino A; Sabatini M; Sestito S; Lenzi P; Raimondi L; Rapposelli S; Biagioni F; Fornai F; Salvetti A; Rossi L; Zucchi R; Chiellini G
    Front Pharmacol; 2017; 8():905. PubMed ID: 29311919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake and metabolic effects of 3-iodothyronamine in hepatocytes.
    Ghelardoni S; Chiellini G; Frascarelli S; Saba A; Zucchi R
    J Endocrinol; 2014 Apr; 221(1):101-10. PubMed ID: 24627446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3-Iodothyronamine: a novel hormone controlling the balance between glucose and lipid utilisation.
    Braulke LJ; Klingenspor M; DeBarber A; Tobias SC; Grandy DK; Scanlan TS; Heldmaier G
    J Comp Physiol B; 2008 Feb; 178(2):167-77. PubMed ID: 17912534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Reprogramming by 3-Iodothyronamine (T1AM): A New Perspective to Reverse Obesity through Co-Regulation of Sirtuin 4 and 6 Expression.
    Assadi-Porter FM; Reiland H; Sabatini M; Lorenzini L; Carnicelli V; Rogowski M; Selen Alpergin ES; Tonelli M; Ghelardoni S; Saba A; Zucchi R; Chiellini G
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29786646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic profiling reveals reprogramming of lipid metabolic pathways in treatment of polycystic ovary syndrome with 3-iodothyronamine.
    Selen Alpergin ES; Bolandnazar Z; Sabatini M; Rogowski M; Chiellini G; Zucchi R; Assadi-Porter FM
    Physiol Rep; 2017 Jan; 5(1):. PubMed ID: 28082426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-iodothyronamine differentially modulates α-2A-adrenergic receptor-mediated signaling.
    Dinter J; Mühlhaus J; Jacobi SF; Wienchol CL; Cöster M; Meister J; Hoefig CS; Müller A; Köhrle J; Grüters A; Krude H; Mittag J; Schöneberg T; Kleinau G; Biebermann H
    J Mol Endocrinol; 2015 Jun; 54(3):205-16. PubMed ID: 25878061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inverse agonistic action of 3-iodothyronamine at the human trace amine-associated receptor 5.
    Dinter J; Mühlhaus J; Wienchol CL; Yi CX; Nürnberg D; Morin S; Grüters A; Köhrle J; Schöneberg T; Tschöp M; Krude H; Kleinau G; Biebermann H
    PLoS One; 2015; 10(2):e0117774. PubMed ID: 25706283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-Iodothyronamine Affects Thermogenic Substrates' Mobilization in Brown Adipocytes.
    Gencarelli M; Laurino A; Landucci E; Buonvicino D; Mazzantini C; Chiellini G; Raimondi L
    Biology (Basel); 2020 May; 9(5):. PubMed ID: 32375297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue distribution and cardiac metabolism of 3-iodothyronamine.
    Saba A; Chiellini G; Frascarelli S; Marchini M; Ghelardoni S; Raffaelli A; Tonacchera M; Vitti P; Scanlan TS; Zucchi R
    Endocrinology; 2010 Oct; 151(10):5063-73. PubMed ID: 20739399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of scopolamine pretreatment on 3-iodothyronamine (T1AM) effects on memory and pain in mice.
    Laurino A; Lucenteforte E; De Siena G; Raimondi L
    Horm Behav; 2017 Aug; 94():93-96. PubMed ID: 28711308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central Effects of 3-Iodothyronamine Reveal a Novel Role for Mitochondrial Monoamine Oxidases.
    Laurino A; Landucci E; Raimondi L
    Front Endocrinol (Lausanne); 2018; 9():290. PubMed ID: 29928258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D decreases adipocyte lipid storage and increases NAD-SIRT1 pathway in 3T3-L1 adipocytes.
    Chang E; Kim Y
    Nutrition; 2016 Jun; 32(6):702-8. PubMed ID: 26899162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.